ACE inhibitors: back to prime time?

Milan Gupta; Subodh Verma; G B John Mancini

doi:10.1136/hrt.2006.108100

Article Text

Editorial

ACE inhibitors: back to prime time?

Abstract

See articles on pages 1026 and 1081

CV, cardiovascular
EMEA, European Medicines Evaluation Agency
FDA, Federal Drug Agency
MI, myocardial infarction

cost–benefit analysis
hypertension
cardiovascular diseases
ACE inhibitors

https://doi.org/10.1136/hrt.2006.108100

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

Review
Renin: friend or foe?

Morris J Brown
Heart 2007; 93 1026-1033 Published Online First: 08 May 2007. doi: 10.1136/hrt.2006.107706
Original research
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study

Andrew Briggs Borislava Mihaylova Mark Sculpher Alistair Hall Jane Wolstenholme Maarten Simoons Jaap Deckers Roberto Ferrari Willem J Remme Michel Bertrand Kim Fox
Heart 2006; 93 1081-1086 Published Online First: 29 Nov 2006. doi: 10.1136/hrt.2005.086728

Log in using your username and password

Main menu

Log in using your username and password

You are here

Abstract

Statistics from Altmetric.com

Request Permissions

Linked Articles

Read the full text or download the PDF:

Log in using your username and password

Read the full text or download the PDF:

Log in using your username and password